Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of Clinical Investigation

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI116205PMID 8423237PMCID PMC329999
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells

  1993cited by this paper
• Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor.

  1991cited by this paper
• Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines.

  1991cited by this paper
• Interleukin 4 Alone and with γ-Interferon or α-Tumor Necrosis Factor Inhibits Cell Growth and Modulates Cell Surface Antigens on Human Renal Cell Carcinomas

  1991cited by this paper
• Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

  1991cited by this paper
• Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas.

  1991cited by this paper
• Interleukin-4 is a potent mitogen for capillary endothelium.

  1991cited by this paper
• Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin.

  1991cited by this paper
• Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells.

  1991cited by this paper
• Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms

  1990cited by this paper
• Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily

  1990cited by this paper
• Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms.

  1990cited by this paper
• Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory.

  1990cited by this paper
• Expression of high-affinity IL-4 receptors on murine tumour infiltrating lymphocytes and their up-regulation by IL-2.

  1990cited by this paper
• Interleukin‐4 Downregulates Interleukin‐6 Production in Human Peripheral Blood Mononuclear Cells

  1990cited by this paper
• Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores.

  1989cited by this paper
• Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2.

  1989cited by this paper
• Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophores

  1989cited by this paper
• Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?

  1989cited by this paper
• Murine interleukin-4 displays potent anti-tumor activity in vivo.

  1989cited by this paper
• Internalization of human interleukin 4 and transient down-regulation of its receptor in the CD23-inducible Jijoye cells.

  1989cited by this paper
• IL-4 (B cell-stimulatory factor 1) regulates multiple aspects of influenza virus-specific cell-mediated immunity.

  1988cited by this paper
• Up-regulation of interleukin 4/B-cell stimulatory factor 1 receptor expression.

  1988cited by this paper
• Lymphokine regulation of inflammatory processes: interleukin-4 stimulates fibroblast proliferation.

  1988cited by this paper
• IL-4/B cell stimulatory factor 1 stimulates T cell growth by an IL-2-independent mechanism.

  1988cited by this paper
• B cell growth-promoting activity of recombinant human interleukin 4.

  1987cited by this paper
• High affinity binding of human interleukin 4 to cell lines.

  1987cited by this paper
• Interleukin 4 as an essential factor for in vitro clonal growth of murine connective tissue-type mast cells

  1987cited by this paper
• Characterization of the human B cell stimulatory factor 1 receptor

  1987cited by this paper
• Identification of a T helper cell-derived lymphokine that activates resting T lymphocytes.

  1986cited by this paper
• T-cell and mast cell lines respond to B-cell stimulatory factor 1.

  1986cited by this paper
• B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells.

  1986cited by this paper
• Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

  1986cited by this paper
• Identification of a T cell-derived b cell growth factor distinct from interleukin 2

  1982cited by this paper
• THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS

  1949cited by this paper

• Interleukins as a potential link between obstructive sleep apnea and renal cell carcinoma

  2025cites this paper
• Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer

  2022cites this paper
• Application of bioengineered elastin-like polypeptide-based system for targeted gene delivery in tumor cells

  2022cites this paper
• Exosomes co‐expressing AQP5‐targeting miRNAs and IL‐4 receptor‐binding peptide inhibit the migration of human breast cancer cells

  2020cites this paper
• Development of elastin-like polypeptide for targeted specific gene delivery in vivo

  2020cites this paper
• и (cid:29)13: строение, функция и генетический полиморфизм Interleukin(cid:29)4 and interleukin(cid:29)13 receptors: structure, function and genetic polymorphism

  2020cites this paper
• Surface receptor‐mediated targeted drug delivery systems for enhanced cancer treatment: A state‐of‐the‐art review

  2020cites this paper
• Targeting Receptors on Cancer Cells with Protein Toxins

  2020cites this paper
• A Bayesian Hierarchical Framework for Pathway Analysis in Genome-Wide Association Studies

  2020cites this paper
• The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice

  2019cites this paper
• Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines

  2019cites this paper
• Functional analysis of protein disulfide isomerase P5 in glioblastoma cells as a novel anticancer target.

  2018cites this paper
• Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo

  2017cites this paper
• Immunotoxin Therapy for Brain Tumors

  2017cites this paper
• Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis

  2017cites this paper
• Design and Modification of Anticancer Peptides

  2016cites this paper
• Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box.

  2016cites this paper
• Tumor growth suppressive effect of IL-4 through p21-mediated activation of STAT6 in IL-4Rα overexpressed melanoma models

  2016cites this paper
• Association of IL-4 and IL-4 receptor gene polymorphisms with the risk , immunotherapeutic effects and prognosis of advanced renal cell carcinoma

  2016cites this paper
• Autocrine interferon-γ may affect malignant behavior and sensitivity to tamoxifen of MCF-7 via estrogen receptor β subtype.

  2015cites this paper
• Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer

  2015cites this paper
• Targeting of IL-4 and IL-13 receptors for cancer therapy.

  2015cites this paper
• Targeting IL4/IL4R for the treatment of epithelial cancer metastasis

  2015cites this paper
• Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: A pilot study

  2014cites this paper
• Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease

  2014cites this paper
• Construction and Application of Elastin Like Polypeptide Containing IL-4 Receptor Targeting Peptide

  2013cites this paper
• Interleukin-4 Induces Senescence in Human Renal Carcinoma Cell Lines through STAT6 and p38 MAPK*

  2013cites this paper
• IL-4 induces cellular senescence through STAT 6 and p 38 MAPK 1 IL-4 induces senescence in human renal carcinoma cell lines through STAT 6 and p 38 MAPK

  2013cites this paper
• mesothelioma xenografts Interleukin-4 receptor cytotoxin as therapy for human malignant pleural

  2013cites this paper
• Induction of Interferon-Stimulated Genes on the IL-4 Response Axis by Epstein-Barr Virus Infected Human B Cells; Relevance to Cellular Transformation

  2013cites this paper
• Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation

  2012cites this paper
• Associations between three polymorphisms in the interleukin-4 receptor gene and risk of cancer: a meta-analysis.

  2012cites this paper
• Synthesis of Homing Peptide-Immobilized Magnetite Nanoparticles through PEG Spacer and Their Biomedical Applications

  2012cites this paper
• Insight of key factors influencing tumor targeting characteristics of glycol chitosan-based nanoparticles and In vivo applications

  2012cites this paper
• Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses.

  2012cites this paper
• Facilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues.

  2012cites this paper
• Toxin-Based Targeted Therapy for Malignant Brain Tumors

  2012cites this paper
• Lycopene Enhances Antioxidant Enzyme Activities and Immunity Function in N-Methyl-N′-nitro-N-nitrosoguanidine–Induced Gastric Cancer Rats

  2011cites this paper
• Genetic Variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality

  2011cites this paper
• Targeting Interleukin-4 Receptor α with Hybrid Peptide for Effective Cancer Therapy

  2011cites this paper
• Association of IL‐4 −590 T>C polymorphism and risk of renal cell carcinoma in a Chinese population

  2010cites this paper
• Challenges in clinical design of immunotherapy trials for malignant glioma.

  2010cites this paper
• Anti-IL-2 and Anti-IL-4 Monoclonal Antibodies Do Not Synergize in the Suppression of Mouse Renal Cancer

  2010cites this paper
• Paradoxical Roles of IL-4 in Tumor Immunity

  2009cites this paper
• IL‐4 blocks M‐CSF‐dependent macrophage proliferation by inducing p21Waf1 in a STAT6‐dependent way

  2009cites this paper
• Homeostatic Regulation of Interleukin-4-Mediated Cell Signaling

  2009cites this paper
• A review of studies on targeting interleukin 4 receptor for central nervous system malignancy.

  2009cites this paper
• Antimetastatic and immunomodulating effect of water extracts from various mushrooms.

  2009cites this paper
• Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma.

  2008cites this paper
• PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.

  2008cites this paper
• Mecanismos moleculares que regulan la activación clásica y alternativa en los macrófagos

  2008cites this paper
• STAT6 Mediates Apoptosis of Human Coronary Arterial Endothelial Cells by Interleukin-13

  2008cites this paper
• Increasing Tumor Cell Resistance to Apoptosis Endogenous Interleukin-4 Promotes Tumor Development by Updated

  2008cites this paper
• Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis.

  2008cites this paper
• PTP 1 B is a negative regulator of interleukin 4 – induced STAT 6 signaling

  2008cites this paper
• Procathepsin D expression correlates with invasive and metastatic phenotype of MDA-MB-231 derived cell lines.

  2007cites this paper
• T-Cell Protein Tyrosine Phosphatase, Distinctively Expressed in Activated-B-Cell-Like Diffuse Large B-Cell Lymphomas, Is the Nuclear Phosphatase of STAT6

  2007influential citation
• Sensitization of colorectal cancer cells to irradiation by IL-4 and IL-10 is associated with inhibition of NF-kappaB.

  2007cites this paper
• Expression and structure of interleukin 4 receptor (IL-4R) complex in human invasive pituitary adenomas.

  2007cites this paper
• Interleukin-4 Promoter Polymorphisms: A Genetic Prognostic Factor for Survival in Metastatic Renal Cell Carcinoma

  2007cites this paper
• Interleukin-4/13 and Cancer

  2007cites this paper
• IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway

  2007cites this paper
• Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma

  2007cites this paper
• Interleuldn 4 Regulates G1 Cell Cycle Progression in Gastric Carcinoma Cells 1

  2007cites this paper
• Carcinoma Cells Cell Cycle Progression in Gastric 1 Interleukin 4 Regulates G

  2007cites this paper
• Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51

  2007cites this paper
• Human Carcinoma Interleukin 4-Toxin in Mice with Interleukin 4 Receptor-bearing Increased Antitumor Activity of a Circularly Permuted Updated

  2006cites this paper
• Polymorphism of interleukin (IL)-4 receptor is associated with the risk and the prognosis of epithelial ovarian cancer in Korean women

  2006cites this paper
• Immunotoxins for targeted cancer therapy

  2006cites this paper
• N‐linked glycosylation of IL‐13R0'2 is essential for optimal IL‐13 inhibitory activity

  2006cites this paper
• IL-4 inhibits the TNF-α induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-α to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses

  2006cites this paper
• N -linked glycosylation of IL-13R (cid:1) 2 is essential for optimal IL-13 inhibitory activity

  2006cites this paper
• Transfection of HT-29 and Hep-2 with IL-4R cDNA Increases the Sensitivity of the Cells Towards IL-4

  2006cites this paper
• Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions

  2005cites this paper
• Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2.

  2005cites this paper
• Aberrant Stat 3 Signaling by Interleukin-4 in Malignant Glioma Cells : Involvement of IL-13 R a 2

  2005cites this paper
• Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.

  2005cites this paper
• Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-α transduction

  2005cites this paper
• Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves' disease.

  2004cites this paper
• IL-4 Protects Tumor Cells from Anti-CD95 and Chemotherapeutic Agents via Up-Regulation of Antiapoptotic Proteins1

  2004cites this paper
• Analysis of Antitumor Activity of an Interleukin-13 (IL-13) Receptor-Targeted Cytotoxin Composed of IL-13 Antagonist and Pseudomonas Exotoxin

  2004cites this paper
• nterleukin-4 Receptor Cytotoxin as Therapy for uman Malignant Pleural Mesothelioma

  2004cites this paper
• IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1

  2004cites this paper
• Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer

  2004cites this paper
• Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.

  2004cites this paper
• Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-α-2 in combination with 5-FU

  2004cites this paper
• IL‐6 as an intracrine growth factor for renal carcinoma cell lines

  2004cites this paper
• Up-Regulation of Antiapoptotic Proteins and Chemotherapeutic Agents via IL-4 Protects Tumor Cells from Anti-CD95

  2004cites this paper
• DUB-3, a Cytokine-inducible Deubiquitinating Enzyme That Blocks Proliferation*

  2004cites this paper
• Identification of the Interleukin 4 Receptor (cid:1) Gene as a Direct Target for p73

  2003cites this paper
• Effect of interleukin (IL)-4 cytotoxin on breast tumor growth after in vivo gene transfer of IL-4 receptor alpha chain.

  2003cites this paper
• Identification of the interleukin 4 receptor alpha gene as a direct target for p73.

  2003cites this paper
• Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1.

  2003cites this paper
• Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor α2 chain in vivo

  2003cites this paper
• Cytokines Affect Resistance of Human Renal Tumour Cells to Complement‐Mediated Injury

  2003cites this paper
• Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein.

  2003cites this paper
• Differential chemokine, chemokine receptor, cytokine and cytokine receptor expression in pulmonary adenocarcinoma: diffuse down-regulation is associated with immune evasion and brain metastasis.

  2003cites this paper
• CHAPTER 10 – Interleukin-4

  2003cites this paper
• Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.

  2002cites this paper
• Recombinant fusion toxins for cancer treatment

  2002cites this paper